Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNX102 in advanced solid tumors
NCT04250597Phase 1Terminated
- Sponsor
- GlycoNex
- Start
- Jul 2020
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label trial of GNX102 in solid tumor (advanced stage) (3 arms), sponsored by GlycoNex. Primary endpoint: Maximum Tolerated Dose. Started Jul 2020; status: terminated.
02
Drugs
GNX102
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04250597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04250597.